- Cryptic Circulation: Genomic sequencing confirms that the Mpox virus (Clade IIb) was circulating via sustained human-to-human transmission as early as 2017, five years before its 2022 global declaration as a public health emergency.
- Biological Indicators: The identification of over 40 specific DNA mutations, primarily driven by human APOBEC3 enzymes, serves as a definitive “molecular clock” proving the virus adapted to humans well before the 2022 surge.
- Evolutionary Trajectory: While the 2017 lineage showed signs of “mutational burden” that potentially lowered its fitness, continued surveillance in 2026 emphasizes the divergence between this lineage and the more severe Clade Ib variant.
Long before the 2022 Mpox outbreak dominated global health headlines, the virus was already navigating a silent, undetected path through human populations. New genomic evidence and retrospective DNA sequencing now confirm that the virus had been circulating outside its endemic African regions since at least 2017, effectively hiding in plain sight for half a decade before reaching a critical mass.
This revelation, spearheaded by researchers at the University of Edinburgh and supported by global health authorities, shifts our understanding of Mpox from a series of sporadic zoonotic “spillovers” to a sustained human epidemic that began years earlier than previously recorded. As we navigate the clinical landscape of 2026, these findings provide a foundational look at how viral pathogens adapt through cryptic transmission.
The Molecular Clock: 47 Mutations and the APOBEC3 Signature
The breakthrough came when scientists analyzed the viral DNA of Clade IIb—the lineage responsible for the initial 2022 global wave. To their surprise, they found roughly 47 DNA-letter changes compared to the samples collected between 2017 and 2019. For a virus that typically evolves at a rate of just one mutation per year, this leap was extraordinary.
The nature of these mutations provided the “smoking gun” for human-to-human transmission. The changes were not random; they were overwhelmingly C-to-T transitions, a hallmark of the human APOBEC3 enzyme family. These enzymes are part of the human innate immune system, designed to thwart viral replication by editing viral DNA. However, when a virus survives this process, it carries these edits as a permanent record of its time in a human host.
Clinical Insight: The APOBEC3 Mechanism
The presence of specific “TT to TA” and “GA to AA” changes in the Mpox genome acts as a biological ledger. Because these specific edits are induced by human-specific enzymes, their high frequency in the 2017-2022 samples confirms that the virus was replicating almost exclusively in humans during that period, rather than jumping back and forth from animal reservoirs.
Differentiating the Clades: 2017 vs. 2026 Realities
In the current 2026 public health environment, it is critical to distinguish between the lineages. The 2017-origin virus belongs to Clade IIb, which generally presents with lower mortality rates. This stands in stark contrast to the World Health Organization’s ongoing monitoring of Clade Ib, which triggered a separate emergency in 2024 due to its increased virulence and different transmission dynamics.
The 2017 lineage showed a peculiar evolutionary trait: many of its mutations appeared to be “detrimental” to the virus itself. Researchers noted that the virus was accumulating a “mutational burden” that could have theoretically slowed its spread. However, as 2026 data shows, this did not prevent the virus from establishing a permanent foothold in the global population.
| Feature | Clade IIb (2017 Lineage) | Clade Ib (2024-26 Surge) |
|---|---|---|
| Origin of Cryptic Spread | Circulating since ~2017 | Identified in DRC, mid-2023 |
| Primary Transmission | Global networks/close contact | Heterosexual and household spread |
| Mutational Driver | APOBEC3 editing | Rapid genomic divergence |
Global Implications and Preventative Success
The “undetected transmission” mentioned by WHO Director-General Tedros Adhanom Ghebreyesus years ago has now been quantified. By 2026, the cumulative global case count from the initial Clade IIb wave exceeded 95,000, a far cry from the 780 cases initially reported in June 2022. This exponential growth underscores the danger of ignoring low-level circulation in non-endemic regions.
The medical community has since responded with robust vaccination campaigns. The MVA-BN (JYNNEOS) and LC16m8 vaccines have become the standard of care for at-risk populations. While the mutations seen since 2017 were not “fitness-enhancing” in a traditional sense, they taught public health officials a vital lesson: Mpox is a resilient pathogen capable of maintaining a low-profile human reservoir for years.
“The mutations we see in the virus today are certainly not ones that kill the virus, but they may be dragging it down a little bit. However, we cannot assume the virus won’t evolve to be more efficient if we allow it to circulate unchecked.”
— Emma Hodcroft, University of Bern
As genomic surveillance continues to improve, the 2017 report remains a pivotal turning point in virology. It serves as a reminder that the next pandemic may not start with a bang, but with a series of quiet, “detrimental” mutations in a virus the world thought it already understood.
